Articles

Novo Nordisk and Eli Lilly, the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, analysts say.

Wall Street may be overestimating Arista’s ability to capitalize on AI, and that’s partly because of Nvidia’s growing strength, says an analyst.

Delta is showing strength in a capacity-constrained environment, according to Melius Research.

London’s FTSE 100 was eyeing record levels Friday, as rallying metals and oil prices boosted resources stocks, with a stumbling pound and better economic data providing additional support.

Import price index increases 0.3% in March

Crude futures moved higher Friday morning, shaking off weakness seen after the International Energy Agency lowered its forecast for oil-demand growth, with jitters around Middle East tensions providing support.

The U.K.’s Labour party will cruise to victory but is set to face an “uphill struggle” in its fight to revive Britain’s troubled economy, a JPMorgan analyst said Friday.

‘Seasonality Timing System’ shifts into and out of stocks using nothing more than the calendar.

Hard-to-short stocks can soar. But in the process these stocks can become hugely overvalued.

Here’s a look at another strategy to continue a series of articles about ways to diversify beyond broad index strategies in the stock market.

Bearish insiders, bullish individuals and bracing for global conflict.

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn’t increase the risk of suicide.